CLYM

Climb Bio, Inc. - Common Stock (CLYM)

About Climb Bio, Inc. - Common Stock (CLYM)

Climb Bio, Inc. operates as a clinical-stage biotechnology company. The firm develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.

Details

Daily high

$14.44

Daily low

$13.92

Price at open

52 Week High

$18.33

52 Week Low

$1.54

Market cap

807.0M

Dividend yield

Volume

1,222

Avg. volume

1.8M

P/E ratio

-16.97

Climb Bio, Inc. - Common Stock News